<p><strong>纽约和以色列赫兹利亚，2026 年 3 月 3 日（环球新闻通讯社）-- InterCure Ltd.</strong>（纳斯达克：INCR）（特拉维夫证券交易所：INCR）（“ <strong>InterCure</strong>” 或 “ <strong>公司</strong>”）今天宣布，2026 年 2 月 25 日，公司收到了纳斯达克证券市场有限责任公司发出的书面通知（“通知”），指出公司未能遵守纳斯达克上市规则 5450(a)(2)，因为公司普通股的收盘竞标价格在过去 30 个连续交易日内低于每股 1.00 美元。</p>
<p>根据纳斯达克上市规则 5810(c)(3)(A)，公司获得了 180 个日历天的合规期，直到 2026 年 8 月 24 日，以重新符合最低竞标价格要求。要重新符合要求，普通股的收盘竞标价格必须在 180 个日历天的合规期内至少连续 10 个交易日达到或超过每股 1.00 美元。</p>
<p>如果公司在 2026 年 8 月 24 日之前未能符合要求，公司预计将有资格获得额外的 180 个日历天的合规期。为了获得这段额外时间，公司需要提交转让申请，并满足公开持股的市场价值和纳斯达克资本市场的所有其他初始上市标准，除了最低竞标价格要求，并在此期间提供书面通知，表明其打算在此期间纠正缺陷。</p>
<p>公司目前打算监控其普通股的收盘价格，并考虑进行反向股票拆分，前提是获得所有必要的公司和监管批准，作为其重新符合最低竞标价格要求计划的一部分，并相信这一措施，加上其持续的业务和战略举措，将支持在适用的时间框架内恢复合规。在此期间，公司普通股将继续在纳斯达克全球市场上市和交易，并不受纳斯达克发出的书面通知的影响。</p>
<p>如果公司在规定的合规期内，包括纳斯达克可能授予的任何延期，未能重新符合要求，纳斯达克将通知公司其普通股将面临退市。</p>
<p>此公告是根据纳斯达克上市规则 5810(b) 的要求发布的，该规则要求及时披露收到缺陷通知的情况。</p>
<p><strong>关于 InterCure（以 Canndoc 名义经营）</strong></p>
<p>InterCure（以 Canndoc 名义经营）（纳斯达克：INCR）（特拉维夫证券交易所：INCR）是北美以外领先、盈利且增长最快的 cannabis 公司之一。Canndoc 是 InterCure 的全资子公司，是以色列最大的持牌 cannabis 生产商，也是首批提供良好生产规范（GMP）认证和药品级医疗 cannabis 产品的公司之一。InterCure 利用其市场领先的分销网络、一流的国际合作伙伴关系以及高利润的垂直整合 “从种子到销售” 模式，领导北美以外增长最快的全球 cannabis 市场。</p>
<p>欲了解更多信息，请访问：https://www.intercure.co</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据美国联邦证券法的前瞻性声明。前瞻性声明可能包括但不限于关于公司恢复符合纳斯达克最低竞标价格要求的能力、公司可能采取的任何行动的时机和潜在有效性，包括实施反向股票拆分，以及其他非历史事实的声明。这些前瞻性声明通常以 “相信”、“希望”、“可能”、“预期”、“应该”、“打算”、“计划”、“将”、“期望”、“估计”、“项目”、“定位”、“战略” 和类似表达的术语为特征，并基于公司管理层在其经验和对历史趋势、当前条件和预期未来发展的看法下的当前期望、假设和评估。前瞻性声明并不保证未来的表现，并且受到风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些声明中表达或暗示的结果有重大差异。这些风险和不确定性包括但不限于公司满足纳斯达克持续上市要求的能力、获得任何公司行动所需的批准，包括反向股票拆分、市场条件以及公司无法控制的其他因素。有关影响公司的风险和不确定性的更详细信息，请参见公司最近的 20-F 表格年度报告中的 “风险因素” 部分，以及公司已提交和可能提交给美国证券交易委员会的其他文件。除法律要求外，公司不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
<p><strong>公司联系方式：</strong></p>
<p>InterCure Ltd.</p>
<p>首席财务官 Amos Cohen</p>
<p>amos@intercure.co</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk5UTXhPQ00zTkRZMk1qSTBJelV3TURFMU9EYzBPUT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk5UTXhPQ00zTkRZMk1qSTBJelV3TURFMU9EYzBPUT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmU5ZjY0YjEtZjJkMC00NzljLTg2M2ItNGU0YmY3MGYzZmE2LTUwMDE1ODc0OS0yMDI2LTAzLTAzLWVu/tiny/InterCure-Ltd.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmU5ZjY0YjEtZjJkMC00NzljLTg2M2ItNGU0YmY3MGYzZmE2LTUwMDE1ODc0OS0yMDI2LTAzLTAzLWVu/tiny/InterCure-Ltd.png"/></p>

INCR

<p>InterCure Ltd. 收到纳斯达克的通知，指出其未符合最低出价要求，因为其股票连续 30 天交易价格低于 1.00 美元。该公司有直到 2026 年 8 月 24 日的时间来恢复合规，可能通过反向拆股的方式。如果未能实现合规，InterCure 可能面临退市风险。该公司仍在纳斯达克全球市场交易，并致力于监测其股价并实施策略以恢复合规</p>

<p><strong>NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd.</strong>(Nasdaq: INCR) (TASE: INCR) (“ <strong>InterCure</strong>” or the “ <strong>Company</strong>”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company’s closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days.</p>
<div class="lb-trans"><p><strong>纽约和以色列赫兹利亚，2026 年 3 月 3 日（环球新闻通讯社）-- InterCure Ltd.</strong>（纳斯达克：INCR）（特拉维夫证券交易所：INCR）（“ <strong>InterCure</strong>” 或 “ <strong>公司</strong>”）今天宣布，2026 年 2 月 25 日，公司收到了纳斯达克证券市场有限责任公司发出的书面通知（“通知”），指出公司未能遵守纳斯达克上市规则 5450(a)(2)，因为公司普通股的收盘竞标价格在过去 30 个连续交易日内低于每股 1.00 美元。</p>
</div><p>Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until August 24, 2026, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Ordinary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period.</p>
<div class="lb-trans"><p>根据纳斯达克上市规则 5810(c)(3)(A)，公司获得了 180 个日历天的合规期，直到 2026 年 8 月 24 日，以重新符合最低竞标价格要求。要重新符合要求，普通股的收盘竞标价格必须在 180 个日历天的合规期内至少连续 10 个交易日达到或超过每股 1.00 美元。</p>
</div><p>If the Company is not in compliance by August 24, 2026, the Company expects to be eligible for an additional 180-calendar day compliance period. To qualify for this additional time, the Company will be required to submit a transfer application and meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and to provide written notice of its intention to cure the deficiency during such period.</p>
<div class="lb-trans"><p>如果公司在 2026 年 8 月 24 日之前未能符合要求，公司预计将有资格获得额外的 180 个日历天的合规期。为了获得这段额外时间，公司需要提交转让申请，并满足公开持股的市场价值和纳斯达克资本市场的所有其他初始上市标准，除了最低竞标价格要求，并在此期间提供书面通知，表明其打算在此期间纠正缺陷。</p>
</div><p>The Company currently intends monitor the closing price of its Ordinary Shares and to consider effecting a reverse share split, subject to obtaining all required corporate and regulatory approvals, as part of its plan to regain compliance with the minimum bid price requirement, and believes that this measure, together with its ongoing business and strategic initiatives, will support the restoration of compliance within the applicable timeframe. The Company’s Ordinary Shares will continue to be listed and trade on the Nasdaq Global Market during this period, and are unaffected by the receipt of the written notice from Nasdaq.</p>
<div class="lb-trans"><p>公司目前打算监控其普通股的收盘价格，并考虑进行反向股票拆分，前提是获得所有必要的公司和监管批准，作为其重新符合最低竞标价格要求计划的一部分，并相信这一措施，加上其持续的业务和战略举措，将支持在适用的时间框架内恢复合规。在此期间，公司普通股将继续在纳斯达克全球市场上市和交易，并不受纳斯达克发出的书面通知的影响。</p>
</div><p>If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting.</p>
<div class="lb-trans"><p>如果公司在规定的合规期内，包括纳斯达克可能授予的任何延期，未能重新符合要求，纳斯达克将通知公司其普通股将面临退市。</p>
</div><p>This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.</p>
<div class="lb-trans"><p>此公告是根据纳斯达克上市规则 5810(b) 的要求发布的，该规则要求及时披露收到缺陷通知的情况。</p>
</div><p><strong>About InterCure (dba Canndoc)</strong></p>
<div class="lb-trans"><p><strong>关于 InterCure（以 Canndoc 名义经营）</strong></p>
</div><p>InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is the leading, profitable, and one of the fastest growing cannabis companies outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.</p>
<div class="lb-trans"><p>InterCure（以 Canndoc 名义经营）（纳斯达克：INCR）（特拉维夫证券交易所：INCR）是北美以外领先、盈利且增长最快的 cannabis 公司之一。Canndoc 是 InterCure 的全资子公司，是以色列最大的持牌 cannabis 生产商，也是首批提供良好生产规范（GMP）认证和药品级医疗 cannabis 产品的公司之一。InterCure 利用其市场领先的分销网络、一流的国际合作伙伴关系以及高利润的垂直整合 “从种子到销售” 模式，领导北美以外增长最快的全球 cannabis 市场。</p>
</div><p>For more information, visit: https://www.intercure.co</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://www.intercure.co</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements pursuant to U.S. federal securities laws. Forward-looking statements may include, but are not limited to, statements regarding the Company’s ability to regain compliance with Nasdaq’s minimum bid price requirement, the timing and potential effectiveness of any actions the Company may undertake to cure such deficiency, including the implementation of a reverse share split, and other statements that are not historical facts. These forward-looking statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions, and are based on current expectations, assumptions and assessments of the Company’s management in light of its experience and perception of historical trends, current conditions and expected future developments. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others, the Company’s ability to meet Nasdaq’s continued listing requirements, obtain required approvals for any corporate actions, including a reverse share split, market conditions, and other factors beyond the Company’s control. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 20-F and in other filings that the Company has made and may make with the U.S. Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含根据美国联邦证券法的前瞻性声明。前瞻性声明可能包括但不限于关于公司恢复符合纳斯达克最低竞标价格要求的能力、公司可能采取的任何行动的时机和潜在有效性，包括实施反向股票拆分，以及其他非历史事实的声明。这些前瞻性声明通常以 “相信”、“希望”、“可能”、“预期”、“应该”、“打算”、“计划”、“将”、“期望”、“估计”、“项目”、“定位”、“战略” 和类似表达的术语为特征，并基于公司管理层在其经验和对历史趋势、当前条件和预期未来发展的看法下的当前期望、假设和评估。前瞻性声明并不保证未来的表现，并且受到风险和不确定性的影响，这些风险和不确定性可能导致实际结果与这些声明中表达或暗示的结果有重大差异。这些风险和不确定性包括但不限于公司满足纳斯达克持续上市要求的能力、获得任何公司行动所需的批准，包括反向股票拆分、市场条件以及公司无法控制的其他因素。有关影响公司的风险和不确定性的更详细信息，请参见公司最近的 20-F 表格年度报告中的 “风险因素” 部分，以及公司已提交和可能提交给美国证券交易委员会的其他文件。除法律要求外，公司不承担公开更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。</p>
</div><p><strong>Company Contact:</strong></p>
<div class="lb-trans"><p><strong>公司联系方式：</strong></p>
</div><p>InterCure Ltd.</p>
<div class="lb-trans"><p>InterCure Ltd.</p>
</div><p>Amos Cohen, Chief Financial Officer</p>
<div class="lb-trans"><p>首席财务官 Amos Cohen</p>
</div><p>amos@intercure.co</p>
<div class="lb-trans"><p>amos@intercure.co</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMk5UTXhPQ00zTkRZMk1qSTBJelV3TURFMU9EYzBPUT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY2NTMxOCM3NDY2MjI0IzUwMDE1ODc0OQ=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZmU5ZjY0YjEtZjJkMC00NzljLTg2M2ItNGU0YmY3MGYzZmE2LTUwMDE1ODc0OS0yMDI2LTAzLTAzLWVu/tiny/InterCure-Ltd.png" alt="" original-src="https://ml.globenewswire.com/media/ZmU5ZjY0YjEtZjJkMC00NzljLTg2M2ItNGU0YmY3MGYzZmE2LTUwMDE1ODc0OS0yMDI2LTAzLTAzLWVu/tiny/InterCure-Ltd.png"/></p>

InterCure 收到纳斯达克关于最低出价要求的通知 | INCR 股票新闻